EGFR and glioblastoma: Due to the low sensitivity of these biomarkers in serum ctDNA, researchers are analyzing CSF ctDNA, and recently EGFR, PTEN, and IDH1 mutations are detected in ctDNA extracted from the CSF of GBM patients with a sensitivity of 58% compared with 0% for serum35 (Table 1).